Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-08-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于增加2024年度日常关联交易预计额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the increase in the estimated amount of daily related party transactions for the year 2024. It details the nature of these transactions, the related parties involved, pricing policies, financial data of related parties, and the approvals from the board and supervisory committees. The document is a formal disclosure about related party transactions and their estimated limits, which is typical for regulatory compliance and investor information. It is not a financial report like an annual or interim report, nor is it a call transcript, audit report, or other types of filings. It is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS). The document length (8364 characters) and content confirm it is a detailed announcement rather than a brief notice or a report publication announcement.
2024-08-23 Chinese
关于控股股东及其一致行动人部分股份解除质押及再质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the release and re-pledging of shares by the controlling shareholder and its concerted parties. It details the number of shares involved, pledge dates, pledgees, and the impact on shareholding and financing. There is no financial statement, management discussion, or detailed financial data. The document is a regulatory announcement about share pledge status and related financing, not a financial report or earnings release. It fits the category of Capital/Financing Update (CAP) as it concerns financing activities related to share pledges and releases.
2024-06-28 Chinese
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2023 annual profit distribution plan (dividend payment) by Shenzhen BGI Genomics Co., Ltd. It details the dividend amount per share, the total dividend payout, the record date, the ex-dividend date, and related adjustments following the shareholders' meeting approval. It does not contain full financial statements or comprehensive financial performance data but focuses on dividend distribution details. The document length is 3449 characters, which is relatively short and consistent with a dividend announcement rather than a full annual report or interim report. Therefore, this document fits the category of Notice of Dividend Amount (DIV).
2024-06-26 Chinese
关于2024年度为子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the progress of guarantees provided to its subsidiary in 2024. It details the board meeting resolutions, the guarantee amounts, the credit agreement with a bank, and financial data of the subsidiary. The document is an update on financing-related activities, specifically about guarantees and credit facilities extended to a subsidiary. It is not a full financial report, audit report, or earnings release. It is not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it concerns financing activities and guarantees provided by the company to its subsidiary.
2024-06-21 Chinese
关于独立董事取得独立董事培训证明的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding an independent director obtaining an independent director training certificate. It mentions the election of a new independent director and compliance with regulatory training requirements. There is no financial data, no report attached or referenced, and no mention of financial results or corporate governance rules beyond director qualifications. This fits the category of Board/Management Information (MANG), as it relates to changes and qualifications in the company's board of directors.
2024-06-20 Chinese
关于完成董事会、监事会换届选举及聘任高级管理人员、内审内控部负责人、证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the completion of the board of directors, supervisory board re-election, and appointment of senior management personnel, internal audit and control department head, and securities affairs representative. It details the election results, the composition of the new board and committees, and provides biographies of the newly appointed individuals. The document does not contain financial statements or financial performance data but focuses on governance and management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is sufficient and it is not a mere announcement of a report publication, nor is it a certification or regulatory filing. Hence, the classification is MANG with high confidence.
2024-06-18 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.